| Development trends for human monoclonal antibody therapeutics AL Nelson, E Dhimolea, JM Reichert Nature reviews drug discovery 9 (10), 767-774, 2010 | 1277 | 2010 |
| Monoclonal antibody successes in the clinic JM Reichert, CJ Rosensweig, LB Faden, MC Dewitz Nature biotechnology 23 (9), 1073-1078, 2005 | 1087 | 2005 |
| Bispecific antibodies: a mechanistic review of the pipeline AF Labrijn, ML Janmaat, JM Reichert, PWHI Parren Nature reviews Drug discovery 18 (8), 585-608, 2019 | 960 | 2019 |
| Future directions for peptide therapeutics development AA Kaspar, JM Reichert Drug discovery today 18 (17-18), 807-817, 2013 | 844 | 2013 |
| Development trends for monoclonal antibody cancer therapeutics JM Reichert, VE Valge-Archer Nature Reviews Drug Discovery 6 (5), 349-356, 2007 | 538 | 2007 |
| Antibodies to watch in 2019 H Kaplon, JM Reichert MAbs 11 (2), 219-238, 2019 | 463 | 2019 |
| Marketed therapeutic antibodies compendium JM Reichert MAbs 4 (3), 413-415, 2012 | 454 | 2012 |
| Recombinant protein therapeutics—success rates, market trends and values to 2010 AK Pavlou, JM Reichert Nature biotechnology 22 (12), 1513-1519, 2004 | 454 | 2004 |
| Antibodies to watch in 2020 H Kaplon, M Muralidharan, Z Schneider, JM Reichert MAbs 12 (1), 1703531, 2020 | 428 | 2020 |
| Development trends for therapeutic antibody fragments AL Nelson, JM Reichert Nature biotechnology 27 (4), 331-337, 2009 | 403 | 2009 |
| Antibodies to watch in 2013: Mid-year update JM Reichert MAbs 5 (4), 513-517, 2013 | 395* | 2013 |
| Trends in development and approval times for new therapeutics in the United States JM Reichert Nature reviews Drug discovery 2 (9), 695-702, 2003 | 331 | 2003 |
| Monoclonal antibodies as innovative therapeutics JM Reichert Current pharmaceutical biotechnology 9 (6), 423-430, 2008 | 324 | 2008 |
| Antibody-based therapeutics to watch in 2011 JM Reichert MAbs 3 (1), 76-99, 2011 | 313 | 2011 |
| Antibodies to watch in 2017 JM Reichert MAbs 9 (2), 167-181, 2017 | 301 | 2017 |
| Monoclonal antibodies in the clinic JM Reichert Nature biotechnology 19 (9), 819-822, 2001 | 298 | 2001 |
| Antibodies to watch in 2021 H Kaplon, JM Reichert MAbs 13 (1), 1860476, 2021 | 285 | 2021 |
| Antibodies to watch in 2018 H Kaplon, JM Reichert MAbs 10 (2), 183-203, 2018 | 279 | 2018 |
| Antibodies to watch in 2022 H Kaplon, A Chenoweth, S Crescioli, JM Reichert MAbs 14 (1), 2014296, 2022 | 275 | 2022 |
| Marketing approval of mogamulizumab: a triumph for glyco-engineering A Beck, JM Reichert MAbs 4 (4), 419-425, 2012 | 236 | 2012 |
